Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Table 5

BPI ratings of pain interference from baseline to pre-cycle 3/5.

Patient	Adults ()
	Baseline	PC3/5	Diff
009	5.29	5.71	0.42
013	4.43	0.86	−3.57
016	9.43	6.0	−3.43
019	6.8	0	−6.8
Mean	6.49	3.14	3.35

Ratings from the pre-cycle 5 evaluation. Note. Clinically meaningful change is ≥1 point.